OAB and Incontinence

“Falls are the leading cause of accidental death in seniors, and many people don’t know that having bladder control problems makes you about twice as likely to fall over,” said William Gibson, MBChB, MRCP, PhD.

The approval was based on data from the ROBUST I and ROBUST 3 clinical trials.

“New things are being developed and, I believe, at the moment showing great initiative and resolve,” says Justin Chee, MD.

“I think it's important for people to recognize this revolution that's going on, to see that we're going from what fell to why it fell,” says John O. L. DeLancey, MD.

The RENOVA iStim tibial neuromodulation system is a wireless peripheral neurostimulator device that a clinician implants in the patient’s ankle with the patient under local anesthesia.

“Men do well and they don't have a really high risk of outcomes that we don't want them to have and that patients don't want to have, which is really the need to catheterize,” says David A. Ginsberg, MD.

"The majority of patients who get onabotulinumtoxinA (Botox) don't need to use a catheter at all," says David A. Ginsberg, MD.

In a recent study, Michael A. Weber, MD, and co-authors assessed the blood pressure and heart rate profiles of the beta 3 adrenergic receptor agonist vibegron in treating patients with OAB.

"We're moving from an era where it was all based on judgment, and experience, to an era where treatments will be based on firm evidence of the structural failures present in each patient," says John O. L. DeLancey, MD.

“What our studies were looking at was a novel device that could potentially help bridge the gap between [endoscopic treatment and urethroplasty] to achieve endoscopic treatment and achieve greater success,” says Justin Chee, MD.

The FDA previously approved the Ieva Digital Therapeutic System for the treatment of urinary incontinence and pelvic floor strengthening in women.

“Doing this study allows us to say, 'With repeat treatments, we're not seeing a greater risk of retention, and we're not seeing a greater risk of UTI,'" says David A. Ginsberg, MD.

"Spend a few extra minutes to learn about emotions and voiding in your patient," writes Gopal H. Badlani, MD.

"For patients who can maintain a functional implant in-situ, long-term patient satisfaction rates remain high," said Elodie Beels, MD.

"We believed that the drug would work as well in OAB wet as it did in OAB dry, so we're pleased to see that it was statistically significantly better than placebo at the 12-week point for looking at response to both metrics in both group," says David Staskin, MD.

"I think another good take-home message is the importance of the informed consent process," says Una Lee, MD.

"As a committee, we felt that there was a need to put together a document to help field some of the ethical considerations that we run into in clinical care but have very little guidance on," says Anne M. Suskind, MD, MS, FACS, FPMRS.

“Qmax at 1, 3, 6, 9, and 12 months and voiding volume at 3 months were significantly lower in the impaired group than in the preserved group. This suggests that preoperative lower bladder contractility was associated with prolonged deterioration of voiding function,” says Junya Hata, PhD.

“I think the surgeon voice is an important voice to be heard because there's not a lot of avenues for surgeons to be able to be honest and share all the things they've learned and all the things they've experienced with their patients,” says Una Lee, MD, FPMRS.

In this interview, Melissa R. Kaufman, MD, PhD, FACS, describes the promise of a regenerative approach to treating recurrent incontinence in women known as autologous muscle derived cells for urinary sphincter repair (AMDC-USR).

In an effort to destigmatize urinary incontinence, Jai Seth, MD, discusses why it is important to educate the general public about this medical condition so that it can be normalized rather than stigmatized.

As a committee, we felt that there was a need to put together a document to help field some of the ethical considerations that we run into in clinical care but have very little guidance on,” says Anne M. Suskind, MD, MS, FACS, FPMRS.

“One of the study findings that really stood out to me was that so many of the surgeons that we spoke to are…such strong advocates for their patients,” says Wai Lee, MD.

“The take-home message is vibegron is a very safe drug and there are no concerns about any kind of cardiovascular adverse effects,” says Michael A. Weber, MD.

“The goals of [this phase of the] trial were to confirm system performance, to evaluate patient compliance, and to determine daily stimulation duration,” said Dr. Steven W. Siegel.